#obesity-treatments

[ follow ]
#medicare #glp-1-drugs #drug-pricing #novo-nordisk #glp-1-treatments #forecast-cuts #mergers--acquisitions
fromFortune
1 week ago

Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune

President Donald Trump has announced a landmark deal aiming to expand Medicare coverage to include certain weight-loss medications, a move that could dramatically change access to these treatments for millions of older Americans. On November 6, Trump revealed that his administration had struck agreements with Eli Lilly and Novo Nordisk, the makers of popular weight-loss drugs including Ozempic and Wegovy, to reduce costs and allow for broader Medicare coverage starting in 2026.
US politics
Business
fromwww.theguardian.com
1 week ago

Ozempic maker Novo Nordisk cuts sales and profit forecasts again

Novo Nordisk cut sales and profit forecasts due to slowed profit growth and intensifying competition in the GLP-1 obesity and diabetes market.
Business
fromIrish Independent
1 month ago

Pfizer makes $4.9bn bet on obesity drugs

Pfizer will acquire obesity startup Metsera for about $4.9bn, paying $47.50 per share plus up to $22.50 in milestone-based payments.
Alternative medicine
fromtime.com
6 months ago

Which Weight-Loss Drug Works the Best?

Zepbound shows superior weight loss compared to Wegovy in a recent clinical trial, influencing treatment decisions for obesity management.
[ Load more ]